SDI (SDI) H1 2025 earnings summary

Executive summary

• Revenue for 1H FY25 was AUD 51.5 million, down 1.3% year-over-year, with strong growth in Europe and Brazil offset by declines in Australia, North America, and the Middle East/Asia.

• Gross margin rose 200 basis points to 63.5%, driven by operational efficiencies and favorable product and regional mix.

• Net profit after tax increased 3.5% to AUD 3.8 million, while EBITDA declined 4.4% to AUD 8.6 million.

• Stela, a new posterior restorative product, achieved AUD 1.3 million in sales in the December half and is positioned as a key growth driver.

• Continued investment in R&D, capital expenditure, and automation to support future growth and new product launches.

Financial highlights

• Gross profit margin improved to 63.5%, up 200 basis points from the prior year.

• EBITDA was AUD 8.6 million, down 4.4% from the previous year.

• Net profit after tax reached AUD 3.8 million, a significant increase from the prior year.

• Operating expenses rose 4.3% to AUD 27.1 million, mainly due to inflationary pressures.

• Cash decreased by AUD 1.4 million after investments and debt reduction.

Outlook and guidance

• Gross margin is expected to be maintained in the second half, with further improvements anticipated in FY 2026 as full operational efficiencies are realized.

• Focus remains on Aesthetics and Whitening products, with 2–3 new product launches expected in the next 12 months.

• Project Montrose manufacturing upgrade ($56m) to commence in August 2025, targeting >$200m sales capacity and >20% ROI.

• Amalgam sales will continue to decline double digits, with a full market exit by 2028; focus is on replacing these with aesthetic product sales.

• International Dental Show in Germany to showcase new innovations.